Jo-Anne H. Young, M.D.

• Associate Professor
• Department of Medicine
• University of Minnesota
• Director of the Program in Transplant Infectious Disease
• Department of Medicine
• University of Minnesota Medical Center
• Minneapolis, Minnesota

A neuropsychological examination at 8 years of age revealed normal mental performance antifungal research buy cheap mentax 15 mg, but with a low attention score and subnormal capacity regarding figurative memory antifungal essential oil blend mentax 15 mg purchase visa. Plans were made for long-term surveillance of the infant because of the potential for thyroid cancer (22) fungus culture order mentax canada. The time required for elimination of radioiodine from the milk may be as long as 14 days antifungal jock itch medications order 15 mg mentax otc. For iodine-123 (123I) and iodine-125 (125I) fungus on lips order 15 mg mentax amex, radioactivity may be present in milk for up to 36 hours and 12 days, respectively (29). Aspects of fetal thyroid dose following iodine-131 administration during early stages of pregnancy in patients suffering from benign thyroid disorders. Onset of function in the human fetal thyroid: biochemical and radioautographic studies from organ culture. Beitrag zur Frage der menschlichen Fruchtschadigung durch kunstliche radioaktive Isotope. The effects of radioactive iodine on maternal and fetal thyroid function during pregnancy. Fetal effects of radioactive iodine therapy in a pregnant woman with thyroid cancer. Congenital athyroidism in the newborn infant from intra-uterine radioiodine action. Combined hypothyroidism and hypoparathyroidism in an infant after maternal 131I administration. The amount and form of radioactivity in human milk after lung scanning, renography and placental localization by 131I labelled tracers. Radioactive iodine uptake by thyroid of breastfed infants after maternal blood-volume measurements. The animal data suggest low risk, but the near absence of human pregnancy experience prevents a more complete assessment of the embryo­fetal risk. However, the indication suggests that the maternal benefit, under close medical supervision, may outweigh the unknown risk to the embryo­fetus. It is indicated for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. Because it is a known drug of abuse, sodium oxybate is only available through the Xyrem Success Program, using a centralized pharmacy. The drug is mainly eliminated by metabolism with <5% of unchanged drug appearing in the urine within 6­8 hours after dosing. The molecular weight of 4-hydroxybutyric acid (about 104) and the minimal plasma protein binding suggest that it will cross to the embryo­fetus, but the extensive, rapid metabolism and short half-life should limit the exposure. A brief 2004 case report described a woman in labor who developed mild respiratory depression (2). The event was initially thought to be due to the opioid used for spinal­epidural analgesia. The depression was treated with face mask oxygen and 2 hours later she delivered a healthy newborn with a good Apgar score (scores not specified). The molecular weight of the acid form (4-hydroxybutyric acid) (about 104) and the minimal plasma protein binding (<1%) suggest that it will be excreted into breast milk, but the extensive, rapid metabolism and short half-life (0. The effect of this exposure on a nursing infant is unknown, but sedation and confusion are potential complications. However, because the drug is taken immediately before bedtime, nursing no sooner than 5 hours after a dose to just before the next dose should prevent clinically significant exposure of an infant. The animal data suggest moderate risk, but the absence of human pregnancy experience prevents a complete assessment of the embryo­ fetal risk. However, there is no evidence that other anticholinergic drugs or agents in the subclass of urinary antispasmodics cause developmental toxicity. Nevertheless, until human pregnancy data are available, the safest course is to avoid solifenacin during pregnancy, especially in the 1st trimester. If inadvertent exposure in pregnancy does occur, the embryo­ fetal risks probably are low. Solifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. It is in the same subclass as darifenacin, flavoxate, oxybutynin, and tolterodine, and trospium. One of the metabolites is active, but the concentration is low and is not thought to contribute significantly to clinical activity. When this dose was continued in pregnancy and during lactation, reduced peripartum and postnatal survival, reductions in body weight gain, and delayed physical development (eye opening and vaginal patency) were observed. Solifenacin was not carcinogenic in mice and assays for mutagenicity were negative. The molecular weight (about 363 for the free base) and prolonged plasma elimination half-life suggest that the drug and/or its metabolites will cross to the embryo­fetus. The molecular weight (about 363 for the free base) and prolonged plasma elimination half-life suggest that the drug and/or its metabolites will be excreted into breast milk. Although neonates are particularly sensitive to anticholinergics, two other agents in the anticholinergic class are classified by the American Academy of Pediatrics as compatible with breastfeeding (see Atropine and Scopolamine). The effect of solifenacin exposure in a nursing infant is unknown, but the risk of toxicity probably is low. It should be noted, though, that sorafenib inhibits angiogenesis, a critical component of embryonic and fetal development. The manufacturer recommends that adequate contraception should be used during therapy and for at 2 weeks after completing therapy (1). However, renal cell carcinoma can be fatal, so if a woman requires sorafenib and informed consent is obtained, treatment should not be withheld because of pregnancy. Sorafenib is indicated for the treatment of patients with advanced renal cell carcinoma. After hepatic metabolism, at least eight metabolites have been identified, one of which has activity similar to the parent compound. The drug was clastogenic, in the presence of metabolic activation, in one test but was not mutagenic or clastogenic in other tests. An intermediate in the manufacturing process that also is present in the final product (<0. Specific studies for fertility impairment have not been conducted, but sorafenib does adversely affect male and female reproductive organs. These effects, more pronounced in rats than in mice or dogs, included testicular atrophy and degeneration, oligospermia, degeneration of epididymis, prostate, and seminal vesicles, central necrosis of the corpora lutea, and arrested follicular development at doses that were about 0. The molecular weight (433 for the free acid) and the long elimination half-life suggest that the drug will cross to the embryo and/or fetus. The molecular weight (433 for the free acid) and the long elimination half-life suggest that the drug will be excreted into breast milk. The effects of this exposure on a nursing infant are unknown, but severe toxicity may occur. In adults, hand­foot skin reaction and rash were the most common adverse events, but diarrhea, hemorrhage, and hypertension were also common. Several reviews have examined the use of -adrenergic blockers in human pregnancy, concluding that these agents are relatively safe for the fetus (1­4). Newborns exposed near delivery should be closely observed during the first 24­48 hours for signs and symptoms of blockade. Long-term effects of in utero exposure to this class of drugs have not been studied but warrant evaluation. In a 1996 study, the embryotoxicity of d-sotalol in rats was shown to be related to gestational age and resulted from dose-dependent bradycardia in in vitro (rat embryo culture) and in vivo (pregnant rat) experiments (7). In embryo cultures, the minimum effective concentration (15 mcg/mL) for causing significant bradycardia was about five times the human therapeutic plasma concentration (3 mcg/mL) achieved in pregnant women after a 400-mg oral dose. In nine pregnant rats, a single oral dose (1000 mg/kg) was administered on gestational day 13. No malformations were observed, but a resorption rate of almost 14% was noted (7). No data were provided on the time interval between the last sotalol dose and the collection of plasma samples (9). In a second study, eight women scheduled for elective cesarean section were given 80 mg of the drug orally 3 hours before the procedure (10). A 1990 report described the use of sotalol, 80 mg twice daily, in one woman throughout gestation (11). These results suggested that sotalol accumulated in the amniotic fluid, but not in the fetus. In addition, there was no correlation between the effectiveness of sotalol therapy and maternal blood levels (13). Sotalol was used in 12 pregnant women for the treatment of hypertension (details above) (9). No fetal adverse effects attributable to the drug were observed, but bradycardia (90­110 beats/minute), lasting up to 24 hours, was discovered in five of the six newborns with continuous heart rate monitoring (9). Therapy was eventually changed to amiodarone plus digoxin with return of a normal fetal heart rate and resolution of the fetal edema. No adverse effects of drug exposure, including bradycardia, were noted in the newborn, which was growing normally at 1 year of age (11). Two fetuses did not respond and two severely hydropic fetuses died 1 and 10 days, respectively, after starting sotalol. Of the surviving infants, 11 were doing well and 1 had cerebral atrophy, hypotonia, and developmental delay thought to be due to the arrhythmia and a thromboembolism (15). A 2000 retrospective study evaluated the use of sotalol for fetal tachycardia in 21 pregnant women (16). Twenty paired samples of breast milk and maternal blood were obtained from 5 of the 12 women treated during and after pregnancy with sotalol for hypertension (dosage detailed above) (9). Specific details of dosage and the timing of sample collection in relationship to the last dose were not given. No -blockade effects were observed in the five nursing infants, including the one infant who had bradycardia at birth. The mother of this infant produced the highest concentrations of sotalol in milk (20. A woman treated throughout gestation with sotalol (80 mg twice daily) and flecainide was continued on these drugs during the postpartum period (11). Simultaneous milk and plasma samples were drawn 3 hours after the second dose of the day on the 5th and 7th postpartum days. The study was repeated on the 105th postpartum day, yielding prefeeding milk and serum concentrations 2. No adverse effects were observed in the infant, who continued to develop normally throughout the study period (12). Although symptoms of -blockade, such as bradycardia and hypotension, were not observed in the nursing infants described above, these effects have been noted with other -adrenergic blockers (see also Acebutolol, Atenolol, and Nadolol) and may occur with sotalol. Long-term effects of exposure to blockers from milk have not been studied but warrant evaluation. The American Academy of Pediatrics classifies sotalol as compatible with breastfeeding (17). Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity. Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk. The animal reproduction is not relevant because oral doses were used and the drug is given topically in humans. Moreover, topical use of the drug suspension does not produce quantifiable amounts of spinosad in human plasma. Although the suspension contains an unspecified amount of benzyl alcohol, it is doubtful if sufficient amounts of the additive would be absorbed to cause embryo­fetal toxicity. It is indicated for the topical treatment of head lice infestations in patients 4 years or age or older. The drug has not been detected in the plasma (limit of quantitation 3 ng/mL) after topical use. The suspension contains a nonspecified amount of benzyl alcohol; plasma concentrations of this agent from use of the suspension have not been determined (1). In these species, oral doses of 10­200 mg/kg/day given during organogenesis resulted in no teratogenic effects, but maternal toxicity was noted in rats at 200 mg/kg/day and, in rabbits, at 50 mg/kg/day. A two-generation dietary reproduction studied was performed in male and female rats with oral doses of 3­100 mg/kg/day from 10 to 12 weeks before mating and throughout mating, parturition, and lactation. The 100 mg/kg/day dose was maternal toxic and adverse effects noted were increased dystocia in parturition, decreased gestation survival, litter size, pup body weight, and neonatal survival (1). Comparisons with the human dose were not specified in any of these studies probably because plasma concentrations after topical use are below the level of quantification. Two other published studies examining the effects in rats and rabbits from oral spinosad found results similar to those noted above (2,3). Long-term carcinogenesis studies in mice and rats with oral spinosad were negative. Clinically significant exposure of the embryo­fetus is not expected because plasma concentrations of the drug after topical use are below the level of quantification. However, excretion of clinically significant amounts of the drug into breast milk is unlikely because plasma concentrations of the drug after topical use are below the level of quantification. Although an unspecified amount of benzyl alcohol also is present in the circulation, it is doubtful if sufficient amounts of the additive would be absorbed to cause toxicity in a nursing infant. Evaluation of spinosad in a two-generation dietary reproduction study using Sprague-Dawley rats. Some have commented, however, that spironolactone may be contraindicated during pregnancy based on the known anti-androgenic effects in humans and the feminization observed in male rat fetuses (1). Other investigators consider diuretics in general to be contraindicated in pregnancy, except for patients with cardiovascular disorders, because they do not prevent or alter the course of toxemia and they may decrease placental perfusion (2­4).

Six days after debulking surgery that preserved the pregnancy fungus under ring cheap 15 mg mentax with visa, she received the first cycle of paclitaxel (135 mg/m2) over 24 hours and cisplatin (75 mg/m2) over 4 hours antifungal hair mentax 15 mg purchase on-line. A 2003 report described the pregnancy outcome of a 30-year-old woman treated with carboplatin and paclitaxel during the 2nd and 3rd trimesters (7) anti fungal liquid soap purchase mentax 15 mg amex. She was diagnosed with an advanced stage of serous papillary adenocarcinoma of the ovary in the 1st trimester antifungal essential oils list mentax 15 mg otc. The infant was doing well at 15 months of age with no evidence of neurologic fungus yard pictures 15 mg mentax purchase, renal, growth, or hematologic effects from the exposure (7). In another 2003 report, a 36-year-old woman with breast cancer was treated with paclitaxel (175 mg/m2 every 3 weeks for three cycles) and epirubicin (120 mg/m2 every 3 weeks for four cycles) from the 14th to the 32nd week of pregnancy (8). A 38-year-old woman with breast cancer had been treated with a radical mastectomy followed by four cycles of doxorubicin and cyclophosphamide before pregnancy (10). Another case involving the treatment of ovarian cancer with paclitaxel in pregnancy was reported in 2007 (14). A 39-year-old woman in the 17th week of pregnancy was diagnosed with non­small-cell lung cancer (16). In the 21st week, paclitaxel (175 mg/m2) and cisplatin (75 mg/m2) every 21 days were started. Three cycles had been given when she presented in the 30th week with tonic-clonic seizures caused by brain metastases. Although the infant developed acute respiratory distress shortly after birth, no other abnormalities were found and he was doing well with normal development and growth after 15 months (16). A second case of non­small-cell lung cancer occurring in pregnancy was reported in 2009 (17). The patient had received 5 weeks of treatment when brain metastases were discovered. Following corticosteroids for fetal lung maturity, she underwent a cesarean section to deliver a healthy male baby (no other details provided). The authors concluded that although these levels were probably too low to cause toxicity, potential toxicity could include myelosuppression (especially neutropenia and thrombocytopenia), severe hypersensitivity reactions, nephrotoxicity, and neurotoxicity (18). Because of the potential toxicity, women receiving these agents should not nurse (19). Protective effect of liposome encapsulation on paclitaxel developmental toxicity in the rat. Role of human placental efflux transporter Pglycoprotein in the transfer of buprenorphine, levo-acetylmethadol, and paclitaxel. Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer. Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: case report and review of the literature. Cytotoxic chemotherapy for pregnancy-associated breast cancer: a single institution case series. Neoadjuvant chemotherapy plus radical surgery in locally advance cervical cancer during pregnancy: a case report. Preservation of pregnancy in a patient with advanced ovarian cancer at 20 weeks of gestation: case report and literature review. Paclitaxel and cisplatin in the treatment of metastatic non-small-cell lung cancer during pregnancy. The animal reproduction data suggest risk of developmental toxicity, but the embryo­fetal effects (growth restriction and death) might have been secondary to maternal toxicity. Importantly, the no-effect doses in two animal species were close to the human dose (based on body weight). The use of this agent by a pregnant patient implies that she also will receive or has received chemotherapy that is toxic to the bone marrow and oral mucosa, and possibly to her embryo or fetus as well. The addition of palifermin to decrease maternal oral mucosal toxicity and to allow a more rapid return to a normal intake of food and fluids appears to be an overall embryo­fetal benefit. In this context, although the absence of human pregnancy experience prevents an assessment of the potential for embryo­fetal harm, the maternal benefit appears to outweigh this unknown risk. It is indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support (1). These doses also were maternal toxic (clinical signs and decreased body weight gain/food consumption). Palifermin has been shown to enhance the growth of human epithelial tumor cell lines in vitro and to increase the rate of tumor cell line growth in a human xenograft model (1). The molecular weight of the protein (about 16,300) should preclude passive diffusion, but active transfer, such as occurs with immunoglobulins, is possible. Although this protein has a high molecular weight (16,300), it might be excreted into breast milk, as are other proteins. However, because it stimulates the proliferation, differentiation, and migration of epithelial cells, including epithelial tumor cell lines, the best course is to stop breastfeeding when the mother is being treated. Moreover, the use of palifermin implies that the mother also has received or is receiving myelotoxic chemotherapy, and exposure of a nursing infant to these agents should be avoided. Developmental toxicity, in the absence of maternal toxicity, was not observed in two animal species. Risperidone was carcinogenic in rodents, but the relationship of this effect to humans has not been studied. Although there are no human pregnancy data with paliperidone, there are limited data for risperidone. If paliperidone is used in pregnancy, health care professionals are encouraged to call the toll-free number 800-670-6126 for information about patient enrollment in the Motherisk study. Paliperidone is indicated for the acute and maintenance treatment of schizophrenia. However, in mice and rats, the parent compound risperidone produced pituitary gland adenomas, endocrine pancreas adenomas, and mammary gland adenocarcinomas. This effect in rodents from risperidone and other antipsychotics is thought to be mediated by prolonged dopamine D2 antagonism and hyperprolactinemia. However, preimplantation and postimplantation losses were increased at the maximum dose that also caused slight maternal toxicity. The molecular weight (about 426), moderate plasma protein binding, and long elimination halflife suggest that the drug will cross to the embryo­fetus. Antipsychotics, especially those classified as high potency, can cause extrapyramidal reactions. However, risperidone and its active metabolite, 9-hydroxyrisperidone (paliperidone), are excreted into breast milk (4­6). Concentrations of risperidone and paliperidone were determined in the plasma and milk. Based on a daily milk intake of 150 mL/kg, a nursing infant would have received 0. Although the combined amounts of risperidone and paliperidone measured in breast milk appear to be too low to cause extrapyramidal effects, concern was expressed for other effects, such as neuroleptic malignant syndrome, and effects on cognitive development (4). A 2004 study measured the steady-state plasma and milk concentrations of risperidone and 9-hydroxyrisperidone in two breastfeeding women and one woman with risperidone-induced galactorrhea (5). The galactorrhea was attributed to elevated prolactin concentrations due to the D2 antagonist effects of risperidone. The plasma concentrations of risperidone and the metabolite were <1 and 14 mcg/L, respectively. Although the woman was not nursing, the absolute and relative infant doses were 0. Neither risperidone nor the metabolite was detected in the plasma of the infants and both were developing normally at 9 and 12 months, respectively (5). The dose was changed to 2 mg every evening on day 7 and then to 3 mg every evening on day 10. No drug accumulation was observed and the concentrations of paliperidone always exceeded those of risperidone. Although no adverse effects from exposure to risperidone and paliperidone have been observed, studies have not been conducted to determine if there are long-term effects. Risperidone distribution and excretion into human milk: case report and estimated infant exposure during breast-feeding. However, such reports are unlikely because the drug is indicated only for pediatric patients. Animal reproduction studies and studies for carcinogenicity, mutagenicity, and fertility have not been conducted (1). The molecular weight (about 148,000) suggests that it will not cross, at least in the 1st and 2nd trimesters. Such reports are unlikely because the drug is indicated only for pediatric patients. Moreover, after the colostral phase, even if a lactating woman inadvertently received the drug, the high molecular weight (about 148,000) should prevent excretion of the monoclonal antibody into breast milk. The animal data suggest that the risk to the human embryo­ fetus is low, but the lack of human pregnancy experience prevents a more complete assessment of the risk. Regarding other agents in this class, there is no human pregnancy experience with dolasetron and granisetron, but limited experience with ondansetron has not demonstrated embryo or fetal toxicity. Based on this experience and the lack of developmental toxicity in two animal species, palonosetron appears to represent a minimal risk to the human embryo or fetus. Only moderate amounts (about 62%) of palonosetron are bound to plasma proteins and about 50% is metabolized to two inactive compounds. In male and female rats, the highest dose had no effect on fertility or reproductive performance (1). In other tests, palonosetron was not genotoxic but did have clastogenic effects (1). The molecular weight of the free base (about 297), the moderate protein binding and metabolism, and the extended plasma half-life suggest that substantial amounts of active drug will be at the maternal­fetal interface for prolonged periods. The molecular weight of the free base (about 297), the moderate protein binding and metabolism, and the extended plasma half-life suggest that the drug will be excreted into breast milk. Because the use of palonosetron is normally for short periods, the risk of any toxicity in a nursing infant appears remote. Because pamidronate probably crosses the placenta, continuous exposure most likely occurred throughout gestation in six cases. The use of pamidronate is not recommended in women who may become pregnant or during pregnancy. However, based solely on the limited human pregnancy experience, inadvertent exposure does not appear to represent a major risk to the embryo or fetus, but infants should be monitored for hypocalcemia during the first few days after birth. Other agents in this pharmacologic class are alendronate, etidronate, ibandronate, risedronate, tiludronate, and zoledronic acid. In 2-year carcinogenic studies with oral doses, male rats, but not females, had a significant increase in benign adrenal pheochromocytoma. The molecular weight of the free acid (about 233), lack of metabolism, and prolonged elimination half-life suggest that the drug will cross the placenta to the embryo­ fetus. The infant was treated for respiratory distress syndrome, narcotic withdrawal, and hypocalcemia. At 1 year, he was developing normally and his weight, length, and head circumference were at 50th percentile (4). Her only complication during pregnancy was hyperemesis gravidarum in the 1st trimester. Blue sclera, but no dysmorphic features, fractures, or long bone deformities, were noted. Asymptomatic hypocalcemia (ionized calcium below the age-related reference range) was found at 24 hours of age but had resolved at 11 days of age without specific treatment. At that age, a skeletal survey found no evidence of fracture, abnormal bone development, modeling defect, or wormian bones (small irregular bones along the sutures of the cranium, particularly related to the parietal bone) in the skull. Similar to the above case, the woman received the same dose of calcium and vitamin D throughout gestation. The infant inherited osteogenesis imperfecta and had bilateral talipes equinovarus but no fractures. Blue sclera was noted at age 13 days, as were wormian bones on the skull radiograph. At 14 months of age, her growth (weight and length) was normal and she remained free of fracture. Although the prevalence of the deformity in osteogenesis imperfecta is unknown, they had observed a second case among 400 children with the disorder. They concluded that an association between pamidronate and talipes equinovarus could not be excluded but that the possibility of such an association was unlikely (5). At this time, preeclampsia developed and a cesarean section was conducted to give birth to a 1. The infant did well and was discharged from the neonatal intensive care unit at a gestational age of 36 weeks. A 2006 report described the use of pamidronate before four uneventful pregnancies from three women (8). Treatment durations-interval between the last dose and conception (both in months) were: 46­3; 26­3 (first pregnancy) and 26­48 (second pregnancy); and 19­21. A woman with hereditary hyperphosphatasia was treated with pamidronate 1 mg/kg on 3 consecutive days every 4 months for 42 months (9). The patient was given 1000 mg/day of elemental calcium but no vitamin D throughout pregnancy. No structural anomalies, fractures or long bone deformities were noted in the infant. All laboratory tests were normal in the mother and infant shortly after birth and after 14 days of breastfeeding (9). A 2008 review described 51 cases of exposure to bisphosphonates before or during pregnancy: alendronate (N = 32), pamidronate (N = 11), etidronate (N = 5), risedronate (N = 2), and zoledronic acid (N = 1) (10). After the infusion, she pumped and discarded her breast milk for 48 hours and then resumed nursing her infant. After the first dose, her breast milk was collected and separated into two pooled samples (0­24 and 25­48 hours).

Mentax 15 mg order on-line. How to get Rid of a Rash Under Breasts.

There was no significant difference in the number of major defects in all pregnancies (live births plus losses): 4 fungi definition in urdu order 15 mg mentax with mastercard. The three major anomalies in the leflunomide-exposed infants were occult spinal dysraphism chytrid fungus xenopus 15 mg mentax with visa, unilateral uretero pelvic junction obstruction and multicystic kidney disease antifungal liquid equate generic mentax 15 mg visa, and microcephaly fungus jeopardy answers buy cheap mentax. There also was no difference between the groups in terms of functional problems antifungal nasal irrigation buy mentax 15 mg free shipping, but significantly more exposed infants had minor defects (p = 0. In addition, among 19 infants from leflunomide-treated mothers who were not eligible for the cohort study for various reasons, 2 had major anomalies: aplasia cutis congenita in a surviving twin; and multiple defects including the Pierre-Robin sequence, cleft of the soft palate, and chondrodysplasia punctata (mother treated for systemic lupus erythematosus). The data indicated that there was no substantial risk of adverse pregnancy outcome among leflunomide-treated women who undergo the cholestyramine elimination procedure early in pregnancy (10). The molecular weight (about 270) is low enough that excretion into breast milk should be expected. Because of the potential for serious adverse effects and without information on the amount of drug in milk, nursing mothers receiving this drug should probably not breastfeed (2). Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. The use of disease-modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. As an analog of thalidomide, lenalidomide is contraindicated in human pregnancy and in women capable of becoming pregnant. It also is indicated, in combination with dexamethasone, for the treatment of multiple myeloma patients who have received at least prior therapy. Lenalidomide is partly metabolized (about one-third), but the metabolites have not been characterized. Plasma protein binding also is low (about 30%) and the elimination half-life is about 3 hours. Female offspring had slightly lower body weight gains during gestation when bred with male offspring. The molecular weight (about 259), moderate metabolism and plasma protein binding, and the elimination half-life suggest that the drug will cross to the embryo and/or fetus. Lenalidomide is contraindicated in pregnancy and in women who might become pregnant. However, when there is no other alternative, the drug can be used in women of reproductive age if specific conditions to avoid pregnancy are met. These conditions include abstention from heterosexual intercourse, or the use of two methods of reliable birth control. The birth control methods should be used continuously for 4 weeks before starting therapy, during therapy, during therapy delay, and for 4 weeks after the end of therapy. Pregnancy testing should be conducted within 10­14 days and a second test within 24 hours of starting therapy and then weekly during the 1st month. After the first month, pregnancy testing should be conducted monthly in women with regular menstrual cycles or every 2 weeks in women with irregular menstrual cycles. The molecular weight (about 259), moderate metabolism (about one-third) and plasma protein binding (about 30%), and the elimination half-life (about 3 hours) suggest that the drug will be excreted into breast milk. The most serious toxicities were neutropenia, thrombocytopenia, deep venous thrombosis, and pulmonary embolism, but other commonly observed (20%) adverse effects included pruritus, rash, diarrhea, constipation, nausea, nasopharyngitis, fatigue, pyrexia, peripheral edema, arthralgia, and back pain. Because of the uncertainty regarding the amount of drug in milk and the potential for severe toxicity, women being treated with lenalidomide should not breastfeed. The passage of lepirudin across the rat placenta suggests that the agent might also cross the human placenta. The effects of this potential exposure on a human embryo or fetus, including hemorrhage, are unknown. Lepirudin binds to thrombin to directly block the thrombogenic activity of thrombin (1). Despite the high molecular weight of lepirudin (about 6970), the drug crosses the placenta of pregnant rats (1). Because of the similarities between rat and human placentas, exposure of the human embryo­fetus might occur. In another case report, lepirudin was used in the 3rd trimester when heparin-induced thrombosis occurred (8). A 34-year-old woman, breastfeeding a 7-week-old infant, developed a deep vein thrombosis in her calf and was treated with low-molecular-weight heparin (9). The woman continued breastfeeding for the next 6 months while being treated with lepirudin. The above report is consistent with the high molecular weight (about 6970) of lepirudin that suggests excretion into milk does not occur. Even if small amounts are excreted, the polypeptide probably would be digested in the stomach of the infant. Treatment of heparin-induced thrombocytopenia and thrombosis during the first trimester of pregnancy. Heparin-induced thrombocytopenia occurring in the first trimester of pregnancy: successful treatment with lepirudin. Successful pregnancy after pulmonary embolism and heparin-induced thrombocytopenia-case report. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation. However, several reports and reviews have described the use of letrozole for ovulation stimulation, an off-label indication. In a 2005 letter from Novartis to healthcare professionals, the manufacturer warned that the drug should not be used for pregnancy induction because it was teratogenic (Novartis issues breast cancer drug warning. Novartis was aware of 13 women exposed to the drug during pregnancy resulting in two spontaneous abortions and two infants with birth defects (no additional details are available). Because the drug inhibits estrogen synthesis in all tissues, it is contraindicated during pregnancy. Letrozole inhibits the aromatase enzyme, resulting in a reduction of estrogen synthesis in all tissues. It is metabolized to inactive metabolites, weakly bound to plasma proteins, and the terminal elimination half-life is about 2 days (1). The drug was not mutagenic but was a potential clastogen in an in vitro test but not in an in vivo test. In mice, rats, and dogs, letrozole caused sexual inactivity in females and atrophy of the reproductive tract in male and female animals (1). The molecular weight (about 285), low plasma protein binding, and long terminal elimination half-life suggest that exposure of the embryo and/or fetus will occur. A number of studies (2­14) and reviews (15­20) have reported the use of letrozole, alone or with gonadotropins, follicle-stimulating hormone, or metformin for ovarian stimulation. No increase in the incidence of congenital malformations was observed and pregnancy outcomes were comparable or better than when clomiphene citrate was used. Moreover, the molecular weight (about 285), low plasma protein binding, and long terminal elimination half-life (about 2 days) suggest that it will be excreted into breast milk. Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation. Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Use of letrozole in polycystic ovary syndrome patients resistant to clomiphene (abstract). Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. Aromatase inhibitors in women with clomiphene citrate resistance: a randomized, double-blind, placebo-controlled trial. Clomiphene citrate or aromatase inhibitors combined with gonadotropins for superovulation in women undergoing intrauterine inseminations: a prospective randomised trial. Efficacy of letrozole in ovulation induction compared to that of clomiphene citrate in patients with polycystic ovarian syndrome. Reproductive outcome after letrozole versus laparoscopic ovarian drilling for clomipheneresistant polycystic ovary syndrome. Aromatase inhibitors for female infertility: a systematic review of the literature. Leuprolide causes a dose-related increase in the incidence of major malformations in pregnant rabbits, but not in rats (1). The most frequently observed malformations in rabbits were vertebral anomalies and hydrocephalus (J. Increased fetal mortality and decreased fetal weights were observed in both animal species with the higher test doses. The risk of these adverse outcomes is considered greater than the risk of congenital malformations because the affected organs in animal studies do not depend on the presence of gonadal steroids for normal development (J. A 1991 case report described a woman who was treated with leuprolide from days 21 to 38 after her last menstrual period (2). The manufacturer is maintaining a registry of inadvertent human exposures during pregnancy to leuprolide and currently has more than 100 such cases (J. No cases of congenital defects attributable to the drug have been reported, although the numbers are too small to draw conclusions as to the risk for perinatal mortality, low birth weight, or teratogenicity. The outcomes of 18 pregnancies in 17 women who had been exposed to leuprolide early in gestation were described in a 1993 report (3). The results suggested no increased risk for birth defects or pregnancy wastage (3). Normal pregnancy outcome after early maternal exposure to gonadotropin releasing hormone agonist. Gonadotropin-releasing hormone agonist administration in early human pregnancy is associated with normal outcomes. However, racemic albuterol is considered compatible in pregnancy, and there is no apparent reason not to classify levalbuterol the same. Levalbuterol inhalation is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age with reversible obstructive airway disease. It is in the same subclass of 2-adrenergic bronchodilators as albuterol, arformoterol, formoterol, metaproterenol, pirbuterol, salmeterol, and terbutaline. Oral doses up to 110 times the maximum recommended daily inhalation dose were not teratogenic. However, racemic albuterol was teratogenic in mice and rabbits (see also Albuterol). Studies for carcinogenicity and fertility have not been conducted with levalbuterol (see Albuterol). The molecular weight (about 240 for the free base) and elimination half-life suggest that the drug will cross to the embryo­fetus. The molecular weight (about 240 for the free base) and elimination half-life (4 hours) suggest that the drug will be excreted into breast milk. The effect of this exposure on a nursing infant is unknown, but the drug is probably compatible with breastfeeding. Additional data are required before a more complete assessment of embryo­fetal risk can be derived. It is not known if levetiracetam causes folic acid deficiency, but it will usually be combined with other anticonvulsants, some of which may cause folic acid deficiency. Therefore, daily supplementation with 4­5 mg of folic acid, combined with multivitamins that include adequate amounts of other B vitamins, is recommended. If a pregnant patient is receiving levetiracetam, clinicians are encouraged to register her, before pregnancy outcome is known, in the Antiepileptic Drug Pregnancy Registry by calling the toll-free number (888233-2334) (1). Levetiracetam is minimally protein bound (<10%) and is not metabolized by the liver (1,2). Major metabolism occurs by enzymatic hydrolysis of the acetamide group to produce the carboxylic acid metabolite (1). Levetiracetam does not inhibit and is not a high affinity substrate for epoxide hydrolase (1). Reports describing the effects (if any) of levetiracetam on folic acid have not been located. The developmental no-effect dose administered throughout pregnancy and lactation was 0. The low molecular weight (about 170) and the lack of protein binding suggest that exposure of the embryo and fetus should be expected. An estimated 20%­30% of epileptic patients have seizures not well controlled by monotherapy and require anticonvulsant polytherapy (2). Clinical studies of levetiracetam have demonstrated efficacy in partial-onset seizures with a good tolerability profile. In addition, its lack of hepatic metabolism and low protein binding result in a low risk of interaction with other drugs, including other anticonvulsants and oral contraceptives. A 2005 report described the outcomes of 11 pregnancies exposed to levetiracetam that were enrolled in the European Registry of Antiepileptic Drugs and Pregnancy (3). Levetiracetam was used alone in two pregnancies and combined with other antiepileptic agents in nine. The outcomes were one spontaneous abortion, one elective abortion, and nine infants without birth defects. However, three of the infants, one of whom was premature, had very low birth weight (5th percentile) (3). The Lamotrigine Pregnancy Registry, an ongoing project conducted by the manufacturer, was first published in January 1997 (4).

A 38-year-old woman with paranoid-type schizophrenia was started on quetiapine (300 mg/day) after an unsuccessful trial with zuclopenthixol (9) antifungal cream new zealand generic mentax 15 mg with amex. She eventually gave birth to a healthy 3120-g male infant with Apgar scores of 9 and 10 at 1 and 5 minutes new and antifungal xanthones from calophyllum caledonicum discount 15 mg mentax visa, respectively antifungal kidney buy mentax 15 mg overnight delivery. A 33-year-old woman with psychosis was treated with quetiapine (300 mg/day) beginning 2 weeks before conception and continuing during gestation (10) fungus gnat nepenthes purchase mentax 15 mg mastercard. The dose was further reduced by 50 mg/day each week starting 4 weeks before her estimated due date to enable breastfeeding antifungal gel for nose purchase discount mentax on-line. A woman took quetiapine (200 mg/day) throughout pregnancy and gave birth to a term, male infant (11). No information was provided on the pregnancy outcome, but the mother planned to continue the drug while breastfeeding her infant (see below). A 2005 study, involving women from Canada, Israeli, and England, described 151 pregnancy outcomes in women using atypical antipsychotic drugs (12). There were no statistically significant differences, including rates of neonatal complications, between the cases and controls, with the exceptions of low birth weight (10% vs. The low birth weight may have been caused by the increased rate of cigarette smoking (38% vs. A 2006 report mentioned three women treated with quetiapine and other agents during gestation (13). In a second 2006 report, a 33-year-old woman with severe psychotic depression was treated with quetiapine (400 mg/day) and fluvoxamine (200 mg/day) (14). After appropriate counseling, she continued this therapy and conceived; after a normal pregnancy, she delivered a healthy, 2600-g, length 49 cm, female infant with Apgar scores of 9 and 10 at 1 and 5 minutes, respectively. A 26-year-old woman was treated with quetiapine for resistant depression with comorbid chronic pain (15). The dose was increased to 400 mg/day in the 4th month and continued for the remainder of her pregnancy. Other drugs taken throughout pregnancy included oxycodone (20 mg 3 times daily) and fluoxetine (40 mg daily). A 2006 review of prophylactic therapy of bipolar disorder briefly described the effects in pregnancy and breastfeeding of a number of drugs, including (16). Untreated pregnant and nursing women with the disorder are at an increased risk of poor obstetrical outcomes and relapse of affective symptoms. Although the limited data prevented conclusions on the relative safety of the drugs, the author did state that each case needed to be considered separately (16). A 17-year-old pregnant adolescent with bipolar disorder was treated throughout gestation with quetiapine 300 mg/day, venlafaxine 75 mg/day, and trazodone 150 mg/day (17). In the 1st, 2nd, and 3rd trimesters, plasma concentrations of quetiapine were ­27%, ­42%, and ­18%, respectively, of the concentrations at 6 months postpartum. The infant had jitteriness during the first 4 days of life that did not require intervention. A woman with schizophrenia was treated with quetiapine 250 mg/day throughout two consecutive pregnancies (18). Both girls were healthy, the first one at about 2 years of age and the other at about 9 months (18). A 2014 case study described the use of phenelzine (105 mg/day), lithium (900 mg/day), and quetiapine (600 mg/day) in a 31-year-old woman with bipolar affective disorder (19). A 36-year-old woman took quetiapine (200 mg/day) throughout gestation and planned to continue the drug while breastfeeding her term, male infant (11). However, the infant was initially given formula because it was not known how much of the drug was excreted in milk. At 3 weeks postpartum, manually expressed milk samples were obtained before a dose and again at 1, 2, 4, and 6 hours after a dose. Based on a milk intake of 150 mL/kg/day, it was estimated that an exclusively breastfed infant would ingest 0. When the mother was told of these findings, she began exclusive breastfeeding at 8 weeks. No adverse effects of quetiapine were reported and the infant was developing normally at 4. A 2006 report described six women treated with quetiapine and other agents during lactation (13). In three cases, therapy was started before or during pregnancy (gestational age shown in parentheses): quetiapine (50 mg) and paroxetine (40 mg) (18 weeks); quetiapine (75 mg), trazodone (75 mg), and venlafaxine (75 mg) (before conception); and quetiapine (100 mg) and venlafaxine (225 mg) (35. In the other three cases, quetiapine was added after delivery (postpartum weeks shown in parentheses): quetiapine (25 mg), paroxetine (60 mg), and clonazepam (0. Breast milk samples, drawn at variable times after the dose, were obtained between 6. Quetiapine was not detected (<30 nmol/L) in the breast milk of four women (doses 25­75 mg). In the two women taking 100 or 400 mg doses, the quetiapine milk levels were 32 and 264 nmol/L, respectively, and the estimated infant exposures were <0. Milk levels for the other agents were clonazepam (not detected), paroxetine (not detected in three; 776 nmol/L in one; estimated infant exposure <0. At 9­18 months of age, infant behavior was evaluated using the Bayley Scales of Infant Development, Second Edition (13). Four scored within normal limits, whereas two showed mild developmental delay (evaluated at 9 and 12. Based on the limited sample, the authors concluded that there appeared to be no association between developmental outcomes and exposure to the drugs in breast milk (13). In a case described in the Fetal Risk Summary section, a woman took quetiapine 400 mg/day and fluvoxamine 200 mg/day throughout a normal pregnancy (14). She continued this therapy while attempting to breastfeed her healthy female infant. The infant was developing normally and meeting all milestones at 3 months of age (14). Another case, also described in the Fetal Risk Summary section, involved a 26-year-old mother taking quetiapine 400 mg/day, oxycodone 60 mg/day, and fluoxetine 40 mg/day during pregnancy and while breastfeeding her 3-month-old male infant (15). Blood and milk samples were collected before the night quetiapine dose was administered and at various times over a 24-hour period. Sixteen milk samples were collected by manual expression at regular feeding times. The average milk concentration of quetiapine was 41 mcg/L and the milk:plasma ratio was 0. The results of a Denver developmental assessment were consistent with the chronologic age (15). Rahi M, Heikkinen T, Hartter S, Hakkola J, Hakala K, Wallerman O, Wadelius M, Wadelius C, Laine K. Pharmacokinetics and elimination of quetiapine, venlafaxine, and trazodone during pregnancy and postpartum. No teratogenic effects were observed in reproduction studies in rats and rabbits with doses 180 and 1 times the maximum recommended human dose, respectively (1). A subsequent communication raising concerns about the validity of the study in terms of adequate exclusion of diabetes, charting and coding errors in busy medical practices, and the effects of maternal obesity (4) was addressed by the investigators (5). If oligohydramnios occurs, stopping quinapril may resolve the problem but may not improve infant outcome because of irreversible fetal damage (6). Six healthy mothers who had been breastfeeding for at least 2 weeks were given a single 20 mg oral dose of quinapril (12). Although data from women receiving daily doses of the drug are needed, quinapril is probably compatible with nursing. The American Academy of Pediatrics classifies captopril and enalapril as compatible with breastfeeding (see Captopril and Enalapril). In therapeutic doses, the oxytocic properties of quinidine have been rarely observed, but high doses can produce this effect and may result in abortion (3,5). Quinidine has been in use as an antiarrhythmic drug for more than 100 years (6) and in pregnancy, at least back to the 1920s (7­13). Eighth cranial nerve damage has been associated with high doses of the optical isomer, quinine, but not with quinidine (9). Quinidine crosses the placenta and achieves fetal serum levels similar to maternal levels (6,11­13). In a 1979 case, a woman taking 600 mg every 8 hours plus an additional dose of 300 mg (2100 mg/day) had serum and amniotic fluid levels of 5. Three days later, 10 hours after the last dose, a healthy male infant was delivered by elective cesarean section. The cord blood level was greater than those measured in three other reports (6,12,13). In a 1984 study, three women maintained on quinidine (300 mg every 6 hours) and digoxin had serum levels of quinidine at delivery ranging from 0. In a 1985 report, a woman taking quinidine (400 mg every 6 hours) plus digoxin and propranolol had an elective cesarean section 18 hours after the last dose (13). One case involved a woman in whom quinidine doses were escalated during a 6-day interval from 300 mg every 6 hours to 1500 mg every 6 hours (6). On day 8, the dosage was reduced to 1500 mg every 8 hours, then to 1200 mg every 8 hours on day 9, and then stopped on day 10. Amniotic fluid levels of quinidine and the metabolite, 3-hydroxyquinidine, on day 10 were 2. In a surveillance study of Michigan Medicaid recipients involving 229,101 completed pregnancies conducted between 1985 and 1992, 17 newborns had been exposed to quinidine during the 1st trimester (F. The drug has been used in combination with digoxin to treat fetal supraventricular and reciprocating atrioventricular tachycardia (12,13). The authors of one of these reports consider quinidine to be the drug of choice after digoxin for the treatment of persistent fetal tachyarrhythmias (13). A dose of 200 mg quinidine 4 times daily was given for 3 days before worsening preeclampsia with breech presentation required delivery by cesarean section. Combination therapy was continued until term when a healthy, growthrestricted, approximately 2240-g infant was delivered. Intrauterine growth restriction apparently developed after maternal combination therapy was initiated, but a discussion of the cause was not included in the reference, nor was maternal blood pressures given (15). A mother treated with quinidine for a fetal supraventricular tachycardia developed symptoms of quinidine toxicity consisting of severe nausea and vomiting, diarrhea, lightheadedness, and tinnitus (6). Her dosage had been increased during an interval of 6 days in a manner described above, producing serum quinidine levels of 1. These ratios were much higher than those observed in previously reported patients (1). Because the fetal heart rate continued to be elevated, with only occasional reductions to 120­130 beats/minute, and fetal lung maturity had been demonstrated; labor was induced, resulting in the delivery of a 3540-g infant with hydrops fetalis. The infant required pharmacologic therapy to control the supraventricular tachycardia. The maternal toxicity was attributed to the elevated levels of 3hydroxyquinidine, because concentrations of quinidine were in the low- to midtherapeutic range (6). In an in vitro study using plasma from 16 normal pregnant women, quinidine concentrations between 0. Pseudocholinesterase is responsible for the metabolism of succinylcholine and ester-type local anesthetics. The quinidine-induced inhibition of this enzyme, which is already significantly decreased by pregnancy itself, could potentially result in toxicity if these agents were used in a mother maintained on quinidine. Parasitemia with Plasmodium falciparum >12% was shown on blood smears before treatment and then fell to 1% after treatment. Because of fetal distress, thought to be caused by uteroplacental insufficiency as a result of maternal parasitemia or fever, a cesarean section was performed to deliver a 1570-g male infant with Apgar scores of 5 and 7 at 1 and 5 minutes, respectively. Except for respiratory difficulty during the first 6 hours, the infant had an uneventful hospital course, including a negative blood smear for malaria (17). A woman taking 600 mg every 8 hours had milk and serum concentrations determined on the 5th postpartum day, 3 hours after a dose. The American Academy of Pediatrics classifies quinidine as compatible with breastfeeding (18). Fetal supraventricular tachycardia treated with high-dose quinidine: toxicity associated with marked elevation of the metabolite, 3(S)-3-hydroxyquinidine. Ventricular paroxysmal tachycardia: report of a case in a pregnant girl of sixteen years with an apparently normal heart. Uber die auswirkung medikamentoser Behandlung in der Schwangerschaft auf das Gerennungspotential des Neugeborenen. Hydrops from reciprocating atrioventricular tachycardia in a 27-week fetus requiring quinidine for conversion. Fetal ventricular tachycardia associated with nonimmunologic hydrops fetalis: a case report. Inhibitory effect of quinidine on plasma pseudocholinesterase activity in pregnant women. Treatment of severe Falciparum malaria during pregnancy with quinidine and exchange transfusion. Although no increased teratogenic risk can be documented for therapeutic doses, its use during pregnancy should be avoided. However, some investigators believe quinine should be used for the treatment of chloroquine-resistant Plasmodium falciparum malaria (2). These reports usually concern the use of quinine in toxic doses as an abortifacient. Quinine has also been used to induce labor in women with intrauterine fetal death (8).

Long-chain polyunsaturated fatty acid requirements during pregnancy and lactation anti fungal mould wash purchase mentax australia. The small cluster of cardiac defects observed in one study after omeprazole exposure appears to be an errant signal because it has not been confirmed in other studies fungus gnats in house uk buy mentax 15 mg fast delivery. Most likely quinoa anti fungal diet order mentax 15 mg online, cardiac and other defects observed in all studies were the result of many factors fungus on tree trunk buy 15 mg mentax with amex, including possibly the severity of the disease and concurrent use of other drugs antifungal oils order 15 mg mentax with amex. Late appearing major defects may also have been missed due to the timing of some of the data collection. If omeprazole is required or if inadvertent exposure does occur early in gestation, the known risk to the embryo­fetus appears to be low. It is used for the treatment of duodenal and gastric ulcers, erosive esophagitis, and pathologic hypersecretory conditions, such as Zollinger-Ellison syndrome. In reproductive studies in pregnant rats and rabbits, doses up to approximately 345 and 172 times, respectively, the normal human dose produced no evidence of teratogenicity, but dose-related embryo and fetal mortality was observed (1). A dose-dependent increase in gastric cell carcinoid tumors has been observed in rats (1). Other tests for genotoxicity in mice and rats were either borderline or negative (1). In sheep, the fetal:maternal ratio of total omeprazole, after both low and high dose, was 0. Placental passage of omeprazole in humans was demonstrated in a study published in 1989 (3). Twenty women were administered a single 80-mg oral dose of omeprazole the night before scheduled cesarean sections with a mean dosing-to-general anesthesia induction time interval of 853 minutes (range 765­ 977 minutes) (3). The drug concentration in 13 of the 20 infants (both arterial and venous umbilical samples were drawn in most cases) was either 0 or below the minimum detection limit (20 nmol/L). In the remaining seven infants, omeprazole cord blood concentrations ranged from 21 to 109 nmol/L. No adverse effects attributable to the drug were observed either at birth or at follow-up in 7 days (3). A paper published in 1995 described the use of omeprazole, 20 mg daily for esophageal reflux, by a woman in two consecutive pregnancies that were terminated because of severe congenital anomalies-anencephaly in one and severe talipes in the other (4). A woman with Zollinger-Ellison syndrome was treated in two of her three pregnancies with omeprazole (5). Her symptoms were controlled with omeprazole (120 mg/day) which was continued until delivery of a healthy, 2610-g girl. During the third pregnancy, she was treated throughout gestation with omeprazole (180 mg/day) and cimetidine (450 mg/day) and delivered a healthy term 2550-g male infant (5). A number of other pharmaceutical agents, identified only by drug category, were also used by these women. Twenty other offspring were exposed in utero to omeprazole combined either with cimetidine (2 infants) or ranitidine (18 infants). A 2001 study expanded the above data to 955 infants who had been exposed to omeprazole during pregnancy (7). Of these, 863 infants were exposed during the 1st trimester and 39 of these, plus an additional 92 infants, were exposed after the 1st trimester. Eight infants had cardiac defects, seven of which were considered mild or unspecified: ventricular septal defects (N = 5), unspecified (N = 2). The infant with the severe cardiac defect had tetralogy of Fallot plus an eye defect (coloboma plus posterior segment malformation). Defects that appeared two or more times were persistent ductus arteriosus at term (N = 2), hydronephrosis (N = 2), undescended testicle (N = 2), unstable hip (N = 3), and pylorostenosis (N = 2). The author thought that the slight increase in cardiac malformations and the stillbirths may have been random effects (7). A prospective cohort study published in 1998 described the pregnancy outcomes of 113 women exposed to omeprazole (101 during organogenesis) matched with 113 disease-paired controls (exposed to H2-receptor antagonists) and 113 controls who were exposed to nonteratogenic agents (8). All of the subjects and controls had contacted a teratogen information service to inquire about drug exposures during their pregnancy. Omeprazole-exposed women were from Canada (N = 59), Italy (N = 41), and France (N = 13), whereas all of the 226 controls were from Canada (Motherisk Program in Toronto). There were no significant differences between the groups in alcohol use and smoking. However, omeprazole-exposed women used significantly more antipeptic and prokinetic agents (histamine blockers, antacids, sucralfate, bismuth subsalicylate, calcium carbonate, and cisapride) than women in the two control groups. Pregnancy outcomes were determined from information supplied by the women shortly after delivery. The incidence of major anomalies in live births exposed during the 1st trimester in the three groups were 4 of 78 (5. The four malformations in omeprazole-exposed infants were ventricular septal defect, polycystic kidneys, ureteropelvic junction stenosis, and patent ductus arteriosus. In disease-paired controls, the three defects were atrial septal defect and two cases of ventricular septal defect, whereas in nonteratogenic controls the two malformations were atrial septal defect with pulmonary stenosis and developmental delay. Although the study lacked the statistical power to detect a small increase in major malformations, the authors concluded that it was unlikely that omeprazole was a major teratogen (8). A 1998 noninterventional observational cohort study described the outcomes of pregnancies in women who had been prescribed 1 of 34 newly marketed drugs by general practitioners in England (9). The pregnancy outcomes of nine women who had taken omeprazole (20­60 mg/day) during gestation were described in a 1998 publication (10). Four of the women took omeprazole during the 1st trimester and five started treatment in the 2nd or 3rd trimesters. No complications or congenital malformations were observed in the offspring or during subsequent follow-up periods ranging from 2 to 12 years (10). From a total of 51 women who had filled a prescription for these drugs sometime during pregnancy, 38 (omeprazole N = 35, lansoprazole N = 3) had done so during the interval of 30 days before conception to the end of the 1st trimester. A control group, consisting of 13,327 pregnancies in which the mother had not obtained a prescription for reimbursed medication from 30 days before conception to the end of her pregnancy, was used for comparison. Compared with controls, the adjusted (for maternal age, birth order, gestational age, and smoking, but not for alcohol abuse) relative risks for the three outcomes were congenital malformations 1. Two databases, one from England and the other from Italy, were combined in a study published in 1999 that was designed to assess the incidence of congenital malformations in women who had received a prescription for an acid-suppressing drug (omeprazole, cimetidine, or ranitidine) during the 1st trimester (12). The malformations were (shown by system): head/face (tongue tie), heart (septal defects N = 2), muscle/skeletal (dysplastic hip/dislocation/clicking hip), and genital/urinary (congenital hydrocele/inguinal hernia). In comparison, the outcomes of 1547 nonexposed pregnancies included 1560 live births (115 [7. Twenty-one newborns were small for gestational age and 78 had a small head circumference for gestational age. Previous treatment with ranitidine (late 1st trimester), cisapride (2nd trimester), or a combination of the two had been unsuccessful. A slightly premature male child (birth weight not given) with fetal bradycardia was delivered in the 36th week with Apgar scores of 6 and 9 at 1 and 5 minutes, respectively. In the five cohort studies analyzed, there were 593 infants, mostly exposed to omeprazole, but also including lansoprazole and pantoprazole. A 2005 study by the European Network of Teratology Information Services reported the outcomes of pregnancies exposed to omeprazole (N = 295), lansoprazole (N = 62), or pantoprazole (N = 53) (15). A population-based observational cohort study formed by linking data from three Swedish national health care registers over a 10-year period (1995­ 2004) was reported in 2009 (16). The main outcome measure was a diagnosis of allergic disease or a prescription for asthma or allergy medications. Several limitations of the study that might have affected their findings were identified, including a general increase in childhood asthma but not necessarily an increase in allergic asthma (16). Several investigations have studied the effect of omeprazole for prophylaxis against aspiration pneumonitis in emergency cesarean section (17­22). An accompanying editorial discussed the strengths and weaknesses of the study (25). A large retrospective cohort study from Israel covering the period 1998­2009 was published in 2012 (28). Among 114,960 live births, there were 110,783 singletons and 1239 elective abortions. Moreover, additional analysis revealed that exposure during the 3rd trimester was not associated with increased risk of perinatal mortality, premature delivery, low birth weight, or low Apgar scores (28). Because there are either very limited or no human pregnancy data for the three newest agents in this class (dexlansoprazole, esomeprazole, and rabeprazole), other drugs in the class are preferred. The milk was obtained by expressing but the volume of the samples was not specified. Maternal serum concentrations began to rise 90 minutes after the dose, reached 950 nM at 12 noon, and appeared to be still rising. Breast milk levels also began to rise at 90 minutes and peaked at 180 minutes at 58 nM. The above case report estimated a maximum daily omeprazole exposure of 4 mcg, but the calculation was based on a consumption of only 200 mL of milk/day for a 5-kg infant (40 mL/kg/day). Moreover, the milk samples were obtained by expression and the volumes expressed were not given. This is clinically relevant because hindmilk obtained at the end of a feeding is 4­5 times higher in fat than foremilk (35). For lipid-soluble drugs, such as omeprazole, hindmilk would be expected to contain most of the drug in milk. In concurrence with the above case report, the molecular weight of omeprazole (about 345) suggests that it will be excreted into human milk. One source stated that the safety of a drug during breastfeeding can be arbitrarily defined as no more than 10% of the adult dose standardized by weight if a therapeutic dose for infants is not known (34). Until additional studies show that omeprazole meets this criterion, the use of omeprazole during breastfeeding should probably be avoided. Other concerns, such as the carcinogenicity observed in animals and the potential for suppression of gastric acid secretion in the nursing infant, also warrant further study. Effect of single-dose omeprazole on intragastric acidity and volume during obstetric anaesthesia. Use of omeprazole during pregnancy-no hazard demonstrated in 955 infants exposed during pregnancy. Lalkin A, Loebstein R, Addis A, Ramezani-Namin F, Mastroiacovo P, Mazzone T, Vial T, Bonati M, Koren G. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled trial. A comparison of omeprazole and ranitidine for prophylaxis against aspiration pneumonitis in emergency caesarean section. Effects of omeprazole, with and without metoclopramide, in elective obstetric anaesthesia. Intravenous administration of the proton pump inhibitor omeprazole reduces the risk of acid aspiration at emergency cesarean section. Moreover, a large Danish study reported a 2-fold increased risk of cardiac anomalies. Consequently, if indicated, starting ondansetron therapy after 10 weeks of gestation should be considered. It is an antiemetic that is indicated for the prevention and treatment of nausea and vomiting induced by chemotherapy, radiotherapy, and postoperative. The mean elimination half-life of a single 8-mg dose in women of reproductive age (18­40 years) is 3. No adverse effects on fertility or on the fetus were observed in reproduction studies in rats and rabbits with oral doses up to 15 and 30 mg/kg/day, respectively (1). The molecular weight (about 293) and the moderate elimination half-life suggest that the drug will cross to the embryo­fetus, but the extensive metabolism may limit the amount of parent drug crossing the placenta. A healthy 2052-g female infant was delivered at 36 weeks by elective cesarean section. Both drugs were given as an initial dose followed by as-needed doses every 8 hours. No differences were observed between the two groups in terms of duration of hospitalization, nausea score, number of doses received, treatment failures, and daily weight gain. The only adverse effect observed was sedation in 8 women who received promethazine compared with none in the ondansetron group. There were three cases of hypospadias in the ondansetron group compared with one in the other groups (p = 0. The authors commented that the three associations could be chance findings but warranted further study (8). In a 2013 study from Denmark, pregnant women exposed to ondansetron were compared in a 1:4 ratio with women not exposed (9). Although this study found no association with an increased risk of some adverse fetal outcomes, the question whether ondansetron causes birth defects remains unanswered. This is true because the median gestational age when the first ondansetron prescription was filled was 10 weeks. A 2014 letter noted that the above study and a second study from Denmark were presented at the 2013 International Society of Pharmacoepidemiology meeting in Montreal (10). The second Danish study (11), using the same national registries but covering more years (1997­2010 vs. A prospective, randomized, double-blind comparison of the serotonin antagonist ondansetron to a standardized regimen of promethazine for hyperemesis gravidarum. The safety of ondansetron for nausea, and vomiting of pregnancy: a prospective comparative study.

Additional information:

• Fluconazole

References

• Schmitt J, Loehrer PJ Sr. The role of chemotherapy in advanced thymoma. J Thorac Oncol 2010;5(10 Suppl 4):S357-S360.
• Robson R, Cecka JM, Opelz G, et al. Prospective registry-based observational cohort study of long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant. 2005;5:2954-2960.
• Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15(1):350-362.
• Cox KL, Frates RC J., Wong A, Gandhi G. Hereditary generalized juvenile polyposis associated with pulmonary arteriovenous malformation. Gastroenterology 1980;78:1566.
• Pieracci FM, Barie PS, Pomp A. Critical care of the bariatric patient. Crit Care Med. 2006;34:1796-1804.
• Pittendrigh CS, Daan S. A functional analysis of circadian pacemakers in nocturnal rodents: IV. Entrainment: pacemaker as clock. J Comp Physiol [A] 1976;106:291-331.